Syntenin regulates Hepatitis C virus sensitivity to neutralizing antibody by promoting E2 secretion through exosomes

Around 71 million people worldwide are infected with the hepatitis C virus (HCV) [1]. Up to 80% of infected individuals are unable to clear the virus and persistently infected individuals have a high risk to develop liver cirrhosis and hepatocellular carcinoma. Direct-acting antivirals (DAA) profoundly increased treatment efficiency, but a prophylactic vaccine required for the global control of new HCV infections is not available.

Source: Journal of Hepatology - March 13, 2019 Category: Gastroenterology Authors: Libin Deng, Wang Jiang, Xiaoning Wang, Andreas Merz, Marie-Sophie Hiet, Yujie Chen, Xiaoyu Pan, Yaming Jiu, Yu Yang, Bowen Yu, Yongnin He, Zhengkun Tu, Junqi Niu, Ralf Bartenschlager, Gang Long Source Type: research